OvaScience (OVAS) Posts Smaller-than-Expected Q2 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
OvaScience Reports Second Quarter 2016 Financial Results
August 4, 2016 4:01 PM EDTAUGMENT revenues increased 30% in 2Q16 compared to 1Q16
Strong financial position enables execution of corporate strategy
Conference call today at 4:30 p.m. ET
WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported its second quarter 2016 financial results and highlighted recent accomplishments.
Following our equity offering in June, which raised net proceeds of approximately $53.9 million, we are in a strong financial position to further expand access... More
